Nasus Pharma (NSRX) Common Equity (2024 - 2025)
Nasus Pharma (NSRX) posted Common Equity of $2.8 million for Q4 2025, up 164.16% quarter-over-quarter from -$4.3 million in Q2 2025, and up 186.18% year-on-year from $967234.1 in Q4 2024.
Nasus Pharma (NSRX) Common Equity (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has reported Common Equity for 2 consecutive years, with $2.8 million the latest figure, recorded in Q4 2025.
- Common Equity for Q4 2025 came in at $2.8 million, up 186.18% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.8 million (up 186.18% YoY), and the FY2025 annual result was $2.8 million, up 186.18% from the prior year.
- Common Equity was $2.8 million for Q4 2025 at Nasus Pharma, up from -$4.3 million in the prior quarter.
- Over five years, Common Equity peaked at $2.8 million in Q4 2025 and troughed at -$4.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 31.20 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 81.19 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -6.61 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 47.38 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 45.93 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 9.19 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 23.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 90.40 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Nasus Pharma | 28.20 Mn | 23.91 Mn | - | 2.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.77 Mn |
| Jun 30, 2025 | -4.31 Mn |
| Dec 31, 2024 | -3.21 Mn |